We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Amgen (AMGN - Free Report) was up +2.89% at $349.81. The stock's performance was ahead of the S&P 500's daily gain of 2.51%. On the other hand, the Dow registered a gain of 2.85%, and the technology-centric Nasdaq increased by 2.8%.
Coming into today, shares of the world's largest biotech drugmaker had lost 9.44% in the past month. In that same time, the Medical sector lost 5.12%, while the S&P 500 lost 1.66%.
The upcoming earnings release of Amgen will be of great interest to investors. The company's earnings per share (EPS) are projected to be $4.74, reflecting a 3.27% decrease from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.51 billion, up 4.42% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $22.22 per share and a revenue of $37.86 billion, demonstrating changes of +1.74% and +3.02%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Amgen possesses a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that Amgen has a Forward P/E ratio of 15.3 right now. This denotes a discount relative to the industry average Forward P/E of 20.4.
It's also important to note that AMGN currently trades at a PEG ratio of 3.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.61.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 143, finds itself in the bottom 42% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to Know
In the latest close session, Amgen (AMGN - Free Report) was up +2.89% at $349.81. The stock's performance was ahead of the S&P 500's daily gain of 2.51%. On the other hand, the Dow registered a gain of 2.85%, and the technology-centric Nasdaq increased by 2.8%.
Coming into today, shares of the world's largest biotech drugmaker had lost 9.44% in the past month. In that same time, the Medical sector lost 5.12%, while the S&P 500 lost 1.66%.
The upcoming earnings release of Amgen will be of great interest to investors. The company's earnings per share (EPS) are projected to be $4.74, reflecting a 3.27% decrease from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.51 billion, up 4.42% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $22.22 per share and a revenue of $37.86 billion, demonstrating changes of +1.74% and +3.02%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Amgen possesses a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that Amgen has a Forward P/E ratio of 15.3 right now. This denotes a discount relative to the industry average Forward P/E of 20.4.
It's also important to note that AMGN currently trades at a PEG ratio of 3.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.61.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 143, finds itself in the bottom 42% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.